藥劑部參考美國 Johns Hopkins 大學研究團隊所建立的 NxP (Nephrotoxic Potential) 專家共識分級清單，本品具「顯著以上腎毒性風險」，被認定具中度至高度腎損傷潛勢，特別是同時合併其他腎毒性藥物、脫水、高齡或既有腎功能異常的患者族群，應更加注意。

【藥品性質提示】 GFR <30 mL/min 以下之慢性腎臟疾病病人，建議勿處方本品 (NSAID)。

止痛消炎口服 Celecoxib is a NSAID with selective inhibition the enzyme, cyclo-oxygenase-2 (COX-2). Celecoxib is indicated for the treatment of osteoarthritis, rheumatoid arthritis, acute pain including primary dysmenorrhea, and is also indicated for reducing the number of colon and rectal polyps in familial adenomatous polyposis (FAP).

Some limited short-term studies in healthy subjects suggest improved gastrointestinal tolerability and lack of platelet effects with celecoxib.

Celecoxib is 97% bound to plasma protein; elimination is via the kidney (27%) and feces (57%). The half-life is 11 hours.

Hypersensitivity to celecoxib; patients with documented allergic-type reaction to sulfonamides; urticaria, asthma, or allergic reactions to aspirin or other nonsteroidal anti-inflammatory agents

C ( prior to 30 weeks gestation ); D (≧30 weeks gestation )

Infant risk can not be ruled out.

Common adverse effects include dyspepsia, diarrhea, and abdominal pain. Although the risk for ulcers and other serious gastrointestinal adverse effects is lower than for other NSAIDs, product labeling still includes warnings about the risk of ulceration, bleeding and perforation.

Adults: osteoarthritis: 200mg PO QD or 100mg PO BID; rheumatoid arthritis: 100-200mg PO BID; acute pain and primary dysmenorrhea: 400 mg initially PO, addition 200mg PRN